CA3072494A1 - Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye - Google Patents

Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye Download PDF

Info

Publication number
CA3072494A1
CA3072494A1 CA3072494A CA3072494A CA3072494A1 CA 3072494 A1 CA3072494 A1 CA 3072494A1 CA 3072494 A CA3072494 A CA 3072494A CA 3072494 A CA3072494 A CA 3072494A CA 3072494 A1 CA3072494 A1 CA 3072494A1
Authority
CA
Canada
Prior art keywords
oil
compositions
composition
patient
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072494A
Other languages
English (en)
French (fr)
Inventor
Scott Whitcup
Orest Olejnik
Mike GARST
Peter A. Simmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akrivista LLC
Original Assignee
Akrivista LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akrivista LLC filed Critical Akrivista LLC
Publication of CA3072494A1 publication Critical patent/CA3072494A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
CA3072494A 2017-08-18 2018-08-17 Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye Pending CA3072494A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547553P 2017-08-18 2017-08-18
US62/547,553 2017-08-18
PCT/US2018/046918 WO2019036625A1 (en) 2017-08-18 2018-08-17 METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE

Publications (1)

Publication Number Publication Date
CA3072494A1 true CA3072494A1 (en) 2019-02-21

Family

ID=65363005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072494A Pending CA3072494A1 (en) 2017-08-18 2018-08-17 Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye

Country Status (7)

Country Link
US (2) US11622982B2 (enExample)
EP (1) EP3668474A4 (enExample)
JP (1) JP7311160B2 (enExample)
CN (2) CN111295169A (enExample)
BR (1) BR112020003276A2 (enExample)
CA (1) CA3072494A1 (enExample)
WO (1) WO2019036625A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524892A (ja) 2016-08-19 2019-09-05 アクリビスタ エルエルシーＡｋｒｉｖｉｓｔａ，Ｌｌｃ ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
WO2019036625A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE
TWI833913B (zh) * 2019-02-27 2024-03-01 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、乙烯系高分子及纖維素系高分子之眼科用組合物
PL3888634T3 (pl) * 2020-03-31 2023-09-11 Oy Finnsusp Ab Preparat oftalmiczny i jego zastosowanie
EP3919047A1 (en) * 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
ES2916152A1 (es) * 2020-12-28 2022-06-28 Univ Valladolid Compuestos para su uso en la prevencion y/o tratamiento de la inflamacion y el estres oxidativo del segmento anterior del ojo
CN112842936A (zh) * 2021-03-15 2021-05-28 傅博 一种眼部清洁液及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4146499A (en) 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
US4585656A (en) 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
CA2052950A1 (en) 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5527488A (en) * 1992-08-07 1996-06-18 Amway Corporation High viscosity anhydrous makeup remover gel
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US20030086986A1 (en) 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7262224B2 (en) * 1999-11-30 2007-08-28 Hanna Isul Skin Therapy, Inc. Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
CA2462272A1 (en) 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
US6559182B1 (en) 2001-11-07 2003-05-06 Purcell Jojoba International, Llc Method for treatment of enveloped viruses using jojoba oil esters
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
WO2006004577A2 (en) 2004-03-12 2006-01-12 Melbj Holdings, Llc Lubricant for the ocular surface
JP5272307B2 (ja) 2004-07-16 2013-08-28 大正製薬株式会社 水性点眼剤
WO2006073786A2 (en) 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US9161905B2 (en) 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
JP2006233398A (ja) 2005-02-23 2006-09-07 Daiwa Kagaku Kogyo Kk アボガド油及びアボガド油不けん化物を処理したことを特徴とする機能化繊維材料および機能化繊維材料の処理方法。
AU2006247136C1 (en) 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
CN101668511A (zh) 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
FR2916636B1 (fr) 2007-05-29 2009-09-04 Octalia Technologies Vehicule sous forme d'une emulsion huile-dans-eau notamment destine a une utilisation ophtalmique ou dermocosmetique
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
CA2764477A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
EP2437762B1 (en) 2009-06-05 2017-08-09 Allergan, Inc. Artificial tears and therapeutic uses
US9119827B2 (en) 2009-06-30 2015-09-01 Lion Corporation Ophthalmic composition
US8909327B1 (en) 2010-06-23 2014-12-09 Allergan, Inc. Instrument and method for diagnosing dry eye in a patient
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
JP6093701B2 (ja) 2011-07-08 2017-03-08 ロート製薬株式会社 眼科用水性組成物
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
EP2787969B1 (en) 2011-12-07 2021-09-29 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
JP5988855B2 (ja) 2012-06-27 2016-09-07 ロート製薬株式会社 水性眼科組成物
WO2015137357A1 (ja) 2014-03-10 2015-09-17 サラヤ株式会社 ソホロリピッドと生理活性物質と油脂とを含有する組成物およびその製造方法
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
LT3266446T (lt) 2016-07-07 2019-01-25 Laboratorios Salvat, S.A. Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą
JP2019524892A (ja) * 2016-08-19 2019-09-05 アクリビスタ エルエルシーＡｋｒｉｖｉｓｔａ，Ｌｌｃ ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
CN106389218A (zh) 2016-10-28 2017-02-15 林振慧 一种眼部凝露
WO2019036625A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE

Also Published As

Publication number Publication date
BR112020003276A2 (pt) 2020-09-01
CN114376961A (zh) 2022-04-22
EP3668474A1 (en) 2020-06-24
US20200164013A1 (en) 2020-05-28
EP3668474A4 (en) 2021-05-26
CN111295169A (zh) 2020-06-16
WO2019036625A1 (en) 2019-02-21
JP2020531462A (ja) 2020-11-05
US20230233637A1 (en) 2023-07-27
US12220439B2 (en) 2025-02-11
JP7311160B2 (ja) 2023-07-19
US11622982B2 (en) 2023-04-11

Similar Documents

Publication Publication Date Title
US12220439B2 (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
US11903986B2 (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
AU2019358249B2 (en) Ophthalmic composition for treatment of dry eye disease
Tauber et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
RU2589837C2 (ru) Искусственные слезы и терапевтические применения
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
CN111182893A (zh) 包含f6h8的眼用组合物
JP2006176499A (ja) 眼疾患治療剤
KR101182115B1 (ko) 나노에멀젼 형태의 안과용 조성물
SA521430043B1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل
US20230093908A1 (en) In-situ Gel Containing Cyclosporine Micelles as Sustained Ophthalmic Drug Delivery System
Wei et al. Antioxidant carbon dots nanozyme loaded in thermosensitive in situ hydrogel system for efficient dry eye disease treatment
BR112021011210A2 (pt) Formulações oftálmicas que proporcionam lubrificação ocular durável
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
JP7358526B2 (ja) 向上した眼の快適性を提供する組成物
HK40073074A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
HK40007121A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
EP4536200A1 (en) Treatment of dry eye disease using mitochondrially targeted antioxidants
HK40028751A (en) Ophthalmic compositions comprising f6h8
Al-Saedi Formulation and in vitro evaluation of cyclosporine A inserts prepared using HPMC for treating dry eye disease
Read serum eyedrops study